Bayer AG Sponsored ADR (BAYRY)
Bayer (BAYRY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Bayer (BAYRY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Bayer acquires rights in Puhe BioPharma cancer drug candidate
Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with China's Puhe BioPharma.
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.
Bayer Stock Slumps After Firm Ordered To Pay More Than $2B in Latest Roundup Case
Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged cancer risk tied to its Roundup weed killer, sending shares of the German pharmaceutical drug giant down Monday.
Is Bayer (BAYRY) Stock Outpacing Its Medical Peers This Year?
Here is how Bayer Aktiengesellschaft (BAYRY) and Enhabit (EHAB) have performed compared to their sector so far this year.
Bayer Shares Plunge After U.S. Court Defeat in Roundup Case
Bayer said it was ordered to pay $2.1 billion in a case about its Roundup weedkiller after a jury in a Georgia state court reached a verdict in favor of the plaintiff.
Bayer hit with $2 billion Roundup verdict in US state of Georgia cancer case
Bayer was ordered by a jury in the U.S. state of Georgia to pay about $2.1 billion to a plaintiff who claimed the company's Roundup weed killer caused his cancer, the plaintiff's law firms said late on Friday.
Is Bayer (BAYRY) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Litigation, Debt, And Decline - Yet Bayer Seems Like A Buy
Bayer's stock surged 24.5% since December 2024, yet remains a speculative investment due to significant risks like high debt and ongoing litigation. 2024 annual results showed a 2.2% sales decline, with only free cash flow improving significantly; Pharmaceuticals saw slight growth, while Crop Science and Consumer Health declined. Bayer's 2025 outlook is uncertain, with potential sales growth of 1% at best; management remains optimistic about a turnaround by 2027.
Bayer's sNDA for Kerendia Label Expansion Gets FDA's Priority Review
The FDA accepts and grants priority review to BAYRY's sNDA for Kerendia to treat patients with a common form of heart failure.
Bayer welcomes new law in U.S. state to better shield it against glyphosate litigation
Bayer said on Monday that it welcomed a new law about to be passed in the U.S. state of Georgia to better protect the maker of crop protection chemicals against glyphosate litigation.
Bayer wins Brazil injunction in soy patent row with farmers
Germany's Bayer has won an injunction to suspend a court ruling that gave Brazilian soybean farmers the right to reimbursement for royalties paid for expired patents of genetically modified soy seeds, according to a farmer group and a statement sent by the company to stakeholders this week.
